Released Aug 9, 2016, after the close
10-Q filed Aug 9, 2016, 40 days after period end · 0001390478-16-000134
Q2 2016 · 10-Q
Revenue—
Net Income$5.39M$5.39M no prior Q2 2015 on fileN/M vs Q1 2016
EPS Diluted$0.58$0.58 no prior Q2 2015 on fileno prior Q1 2016 on file
Operating Income-$9,292,000—
Operating Cash Flowderived-$11,491,000—
Free Cash Flowderived-$11,491,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2016 | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|---|
| Revenue | — | $3.38M | $3.38M | — |
| Net Income | $5.39M | $5.39M | -$15.66M | -$3.75M |
| EPS Diluted | $0.58 | -$0.11 | -$0.03 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR